Herein, we utilized MIF to detect immune features, including densities of immune cells (CD4+ T cells, CD8+ T cells and PD1+ cells) and protein expression of gp96 (a component of the HSPPC-96 vaccine) and MxA (an interferon-stimulating gene product, whose expression reflects interferon-pathway activity) (Figure 1), in FFPE tumor samples that were collected prior to vaccination from all 19 included patients with complete follow-up (24). The gene discussed is HSP90B1; the disease is neoplasm.